Cyclacel Pharmaceuticals Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 73.75. In total, the insiders bought 4 220 559 and sold 12 CYCCP shares in the last 100 trades.

Insider Power

(Last 100 transactions)
73.75
Buy 4 220 559 Shares
Sell 12 Shares

Historical Insider Trades

Date Type Action Person Amount
Dec 21, 2023 Common Stock Buy Mcbarron Paul 1 886
Dec 21, 2023 Warrants (right to buy) Buy Mcbarron Paul 1 886
Dec 21, 2023 Common Stock Buy Rombotis Spiro George 6 070
Dec 21, 2023 Warrants (right to buy) Buy Rombotis Spiro George 6 070
Jun 30, 2023 Stock Option (right to buy) Buy Rombotis Spiro George 110 000
Jun 30, 2023 Stock Option (right to buy) Buy Barker Sam L 42 438
Jun 30, 2023 Common Stock Buy Barker Sam L 21 219
Jun 30, 2023 Stock Option (right to buy) Buy Spiegel Robert J. 42 438
Jun 30, 2023 Common Stock Buy Spiegel Robert J. 21 219
Jun 30, 2023 Stock Option (right to buy) Buy Mcbarron Paul 70 200
Jun 30, 2023 Stock Option (right to buy) Buy Kirschbaum Mark 70 200
Jun 30, 2023 Stock Option (right to buy) Buy Walker Karin L 42 438
Jun 30, 2023 Common Stock Buy Walker Karin L 21 219
Jun 30, 2023 Common Stock Buy Ferguson Kenneth M. 21 219
Jun 30, 2023 Stock Option (right to buy) Buy Ferguson Kenneth M. 42 438
Jun 30, 2023 Stock Option (right to buy) Buy Henney Christopher S 42 438
Jun 30, 2023 Common Stock Buy Henney Christopher S 21 219
Jun 30, 2023 Stock Option (right to buy) Buy Schwartz Brian 42 438
Jun 30, 2023 Common Stock Buy Schwartz Brian 21 219
Jan 31, 2023 Common Stock Buy Mcbarron Paul 31 200
Jan 31, 2023 Common Stock Buy Rombotis Spiro George 57 600
Jan 31, 2023 Common Stock Buy Kirschbaum Mark 31 200
Jun 14, 2022 Stock Option (right to buy) Buy Ferguson Kenneth M. 47 467
Jun 14, 2022 Common Stock Buy Ferguson Kenneth M. 23 733
Jun 14, 2022 Buy Ferguson Kenneth M. 0
Click to get the best stock tips daily for free!

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-... CYCCP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT